How big is Orchestra Biomed Holdings, Inc.?

As of Jun 18, Orchestra Biomed Holdings, Inc. has a market capitalization of 128.73 million, with net sales of 2.89 million and a net profit of -66.32 million over the latest four quarters. Shareholder's funds are 32.96 million, and total assets are 76.17 million as of Dec 24.

Market Cap: As of Jun 18, Orchestra Biomed Holdings, Inc. has a market capitalization of 128.73 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 2.89 million and a net profit of -66.32 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the shareholder's funds amounted to 32.96 million, while total assets were reported at 76.17 million.

What does Orchestra Biomed Holdings, Inc. do?

Orchestra Biomed Holdings, Inc. is a blank check company focused on business combinations in the biopharma and medical technology sectors. As of March 2025, it reported net sales of $1 million and a net loss of $19 million, with a market cap of $128.73 million.

Overview: <BR>Orchestra Biomed Holdings, Inc. is a blank check company in the Pharmaceuticals & Biotechnology industry, targeting business combinations with companies in the biopharma and medical technology sectors.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -19 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 128.73 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.07 <BR>Return on Equity: -393.27% <BR>Price to Book: 7.64<BR><BR>Contact Details: <BR>Address: 412 West 15Th Street, Floor 9, NEW YORK NY: 10011

Should I buy, sell or hold Orchestra Biomed Holdings, Inc.?

Is Orchestra Biomed Holdings, Inc. overvalued or undervalued?

As of February 9, 2023, Orchestra Biomed Holdings, Inc. is considered overvalued and risky, with poor financial metrics and a year-to-date return of -22.5%, significantly underperforming the S&P 500's gain of 2.44%.

As of 9 February 2023, the valuation grade for Orchestra Biomed Holdings, Inc. has moved from does not qualify to risky. The company is currently assessed as overvalued based on its financial metrics. Key ratios include a Price to Book Value of 7.52, an EV to EBIT of -1.34, and a ROE of -393.27%, indicating significant financial distress and a lack of profitability.<BR><BR>In comparison to its peers, Orchestra Biomed's valuation appears unfavorable. For instance, CareDx, Inc. is categorized as very attractive with a P/E ratio of -58.5934, while Surmodics, Inc. also holds a risky status with a P/E of -36.7377. The company's recent stock performance has been poor, with a year-to-date return of -22.5%, significantly lagging behind the S&P 500's gain of 2.44% during the same period, reinforcing the notion of overvaluation.

Is Orchestra Biomed Holdings, Inc. technically bullish or bearish?

As of September 11, 2025, Orchestra Biomed Holdings, Inc. is in a bearish trend with weak strength, indicated by bearish daily moving averages and monthly MACD, and has significantly underperformed the S&P 500 with a year-to-date return of -37.25% compared to the index's 12.22%.

As of 11 September 2025, the technical trend for Orchestra Biomed Holdings, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, indicated by the daily moving averages being bearish and the monthly MACD also showing a bearish signal. The Bollinger Bands are bearish on both weekly and monthly time frames, further supporting this bearish outlook. The KST and OBV show mildly bearish signals on the weekly, but are bearish on the monthly for KST. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -37.25% versus the S&P 500's 12.22%, and a one-year return of -48.67% compared to 17.14% for the index.